Ocular adverse events included eye pain (2/40, 5%), progression of cataract (2/40, 5%), itchy eyes (1/40, 2.5%), conjunctival hemorrhage (1/40, 2.5%), increased intraocular pressure (IOP) (1/40, 2.5%), watering of the eye (1/40, 2.5%), and blepharitis (1/40, 2.5%), which were generally consistent with those of other intravitreal anti-VEGF agents and typical of those seen with intravitreal injections6,11,25. This evidence concerns the gene VEGFA and blepharitis.